Navigation Links
Integrity® Adx Pacemaker

ProductsIntegrity® Adx Pacemaker
Company St. Jude Medical, Inc.
Item Integrity® Adx Pacemaker
Features 
  • AF Suppression Algorithm
  • AF Suppression Histogram
  • Stored Electrograms (EGMs)
  • Auto Mode Switch (AMS) Log
  • Ventricular Rate Control
  • Physician Commanded Atrial Therapy
  • Advanced Hysteresis Response
  • Automatic P & R Wave Measurements
  • Omnisense® Accelerometer Sensor
  • Auto Rest Rate
  • FastPath™ Programmer Software
  • Onscreen Help
  • Previous Test Results
  • Remaining Longevity Estimate
Description The Integrity ADx pacemaker family, which includes the world's smallest dual-chamber pacemaker, provides clinicians with advanced pacemaker technology, including the revolutionary AF Suppression™ algorithm, the first U.S. commercially approved algorithm designed to suppress atrial fibrillation (AF).
Info St. Jude Medical, Inc.
Customer Service: (800) 328-9634
Web site: http://www.sjm.com

Related medicine products :

1. Integrity® Pacemaker
2. Model 3085 Dual-Chamber Temporary Pacemaker
3. Model 3077 Single-Chamber Temporary Pacemaker
4. Affinity™ Pacemaker
5. Identity® Adx Pacemaker
6. Identity® Pacemaker
7. Regency Pacemaker
8. Microny® Pacemaker
9. Trilogy® Pacemaker
10. Verity Adx Pacemaker
11. Affinity™ DR Pacemakers
... capabilities combined with ease of use make the O...r office or hospital-based urodynamics, the OM-5 i...leak point pressure, or urethral pressure profiles...e the OM-5 flexible enough to meet the needs of al...
... a 5 mm suture anchor that incorporates a small mi...for maximum pull-out strength in soft bone. The an...ssibility of locking the second suture after the f...e distal part of the insertion shaft indicates the...
...o use as its name implies. Third-party payers are...herapeutic procedures. For the treatment of patien...requires urodynamics. As a result, urodynamic eva...nvironment, with only complicated cases referred t...
...hute Tissue Anchor allows one step fixation of sof...scopic knotless rotator cuff repair in one simple ... an outside thread diameter of 5 mm and a small 2 ...res securely hold a thin, bioabsorbable PLLA disc ...
Medicine Products:
(Date:10/7/2008)...an Wanted to Know But Was Afraid to Ask!, LOS ANG... babies born,in the U.S. each year but there,s not...AD is a revealing, entertaining and inspirational ...for dads-to-be from fathers who,have recently gone...cludes,a wealth of advice from several experts in ...
(Date:10/7/2008)...Utah researchers have developed a magnetic resonan...antifying injury to the wall of the heart,s left a...o treat atrial fibrillation. The results of the st...e Journal of the American College of Cardiology ....r abnormal heart rhythm, that involves the heart,s...
(Date:10/7/2008)...orm Corporation ( www.wyndstorm.com ) (OTCBB:WYND)...unced a key win with Muve, Inc. ( www.muveinc.com ... design to promote Muve,s activity-based corporate... ultimately help Muve,s corporate clients foster t...teractive messaging, rewards programs, tips, chall...
(Date:10/7/2008)...re-USNewswire/ -- The Catholic Health,Association ...Catholic,Health Initiatives (CHI), Denver; Covenan...h, Novi, MI -- is launching a ministry-wide effort... Through receipt of a $20,000 grant from the Natio...E) and the Catholic Coalition on,Climate Change, t...
Breaking Medicine News(10 mins):Health News:BEING DAD DVD Offers a Sneak Peek at Pregnancy From a Guy's Point of View 2Health News:Novel imaging approach may assist in predicting success of treatment for atrial fibrillation 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 2Health News: 3D Social Media Application Aims to Cut Workplace Obesity : Muve, Inc., Selects Social Media Developer Wyndstorm Corporation to Design Online Promotions for Corporate Wellness Program 3Health News:Catholic Health Organizations Launch Ministry-Wide Effort to Raise Awareness About Global Climate Change 2
...ommon statin may be most effective when taken at n...prescribed to lower cholesterol.// Researchers fro...er 10 milligrams or 20 milligrams of simvastatin, ...ng the drug for primary or secondary prevention of...
...ard hearing aids amplify all sounds, which makes h...ion say researchers. New, all-digital hearing aids... aid automatically distinguishes between speech an...eason somebody comes in for a hearing aid is that ...
...health, put together by the National Center for He... Americans are obese //and two-thirds overweight. ...aching a new record high of 77.2 years in 2001, up...ted States in 2001 can expect to live 79.8 years, ...
...there will be more than 105,000 new cases of colon...agnosed this year in the United States. When the ...ide effects that make quality of life poor. Now, d...lp them live better and with less stress. Clinical...
Other Medicine News:Health News:Diabetes, obesity rates shooting up 2
(Date:10/6/2008)...Newswire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: ...s joining the,Company as Vice President of Investo...h will be responsible for all investor relations,f...al Officer Kurt,Leutzinger., Most recently, Dr. S...,Analyst at JPMorgan Securities, and has been an a...
(Date:10/6/2008)...ACG Annual Scientific Conference -, ORLANDO, Fla....(formerly Microbia) today announced presentation o...ing the role that cyclic guanosine,monophosphate (...studies,demonstrate that cGMP inhibits intestinal ...esia and desensitizes colonic afferent nerves in a...
(Date:10/6/2008)...ies with Durezol Dosed Prior to Surgery, TAMPA, F...nc., a,privately held ophthalmic-focused biopharma... (difluprednate ophthalmic emulsion) 0.05% is now,...d by the U.S. Food and,Drug Administration in June...cated for the treatment of inflammation and pain a...
(Date:10/6/2008)...erate to severe patients achieved endoscopic,respo...emission at Week 10,in data from a 54-week open-la...troenterology (ACG) Annual Scientific Meeting, OR...ented data from a,large, prospective study investi...CD) with a biologic compound. The data presented a...
Breaking Medicine Technology:Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Test Detects Sensitivity to HIV Drug 11202 1Test Detects Sensitivity to HIV Drug 11202 2Gene found to play a suppressor role in skin cancer development 11198 1Gene found to play a suppressor role in skin cancer development 11198 2Elephant Ensemble Theater Brings New Production to Bronx Hospitals 11194 1Gerontology conferences highlights to include talks on student social networking 11190 1Gerontology conferences highlights to include talks on student social networking 11190 2
...ts and physicians should find these data reassurin...all/ --,GlaxoSmithKline said today that findings f...valuated for Cardiac Outcomes and,Regulation of gl...designed specifically to determine cardiovascular ...iabetes, adds further evidence to,the overall card...
...K--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (cetuxim...argeting the epidermal,growth factor receptor (EGF... Incorporated, was the focus of nine oral and 46,p... Annual Meeting,of the American Society of Clinica...ntations showcased the extensive,clinical developm...
Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10